ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2572

Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
Abstract Number: 1736

Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
Abstract Number: 1755

Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways
Abstract Number: 0957

Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc
Abstract Number: 1114

Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Abstract Number: 2589

Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
Abstract Number: 1796

Multi-Tissue Molecular and Histopathological Profiling of Facet Joints and Intervertebral Discs
Abstract Number: 0268

Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies
Abstract Number: 0485

Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Abstract Number: 2350

Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
Abstract Number: 0295

Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Abstract Number: 1414

Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Abstract Number: 0380

Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
Abstract Number: 2108

Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
Abstract Number: 2142

Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].